Login to Your Account

Tremfya gets speedy approval in plaque psoriasis following expedited FDA review

By Marie Powers
News Editor

Thursday, July 13, 2017

The decision by Johnson & Johnson  to use a priority review voucher for the submission of the biologics license application for guselkumab apparently paid off.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription